CY1115382T1 - Συνθεσεις και μεθοδοι για αναστολη toy pdgfrb και toy vegf-a - Google Patents

Συνθεσεις και μεθοδοι για αναστολη toy pdgfrb και toy vegf-a

Info

Publication number
CY1115382T1
CY1115382T1 CY20141100361T CY141100361T CY1115382T1 CY 1115382 T1 CY1115382 T1 CY 1115382T1 CY 20141100361 T CY20141100361 T CY 20141100361T CY 141100361 T CY141100361 T CY 141100361T CY 1115382 T1 CY1115382 T1 CY 1115382T1
Authority
CY
Cyprus
Prior art keywords
vegf
methods
pdgfrβ
compositions
pdgfrb
Prior art date
Application number
CY20141100361T
Other languages
English (en)
Inventor
Pallavur V Sivakumar
Debra G Gilbertson
Marshall D Snavely
George R Mabry
Eugene C Yi
Yue Yao
Scott R Presnell
Original Assignee
Zymogenetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics, Inc. filed Critical Zymogenetics, Inc.
Publication of CY1115382T1 publication Critical patent/CY1115382T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Αποκαλύπτονται ανταγωνιστές του PDGF υποδοχέα β (PDGFRβ) και του VEGF-A, μεταξύ αυτών εξουδετερωτικά αντισώματα αντι-PDGFRβ και εξουδετερωτικά αντισώματα αντι-VEGF-A, καθώς και σχετικές συνθέσεις και μέθοδοι. Στα αντι-PDGFRβ και αντι-VEGF-A αντισώματα που αποκαλύπτονται εδώ περιλαμβάνονται διπλοειδικά αντισώματα ικανά να δεσμευθούν και να εξουδετερώσουν τόσο τον PDGFRβ όσο και τον VEGF-A. Επίσης αποκαλύπτονται μέθοδοι αγωγής νεοαγγειακής διαταραχής, όπως καρκίνου ή νεοαγγειακής οφθαλμικής διαταραχής, χρησιμοποιώντας PDGFRβ και/ή VEGF-A ανταγωνιστή.
CY20141100361T 2008-03-27 2014-05-23 Συνθεσεις και μεθοδοι για αναστολη toy pdgfrb και toy vegf-a CY1115382T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4006808P 2008-03-27 2008-03-27
US14454709P 2009-01-14 2009-01-14
EP09724060.0A EP2274008B1 (en) 2008-03-27 2009-03-27 Compositions and methods for inhibiting pdgfrbeta and vegf-a

Publications (1)

Publication Number Publication Date
CY1115382T1 true CY1115382T1 (el) 2017-01-04

Family

ID=40793092

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100361T CY1115382T1 (el) 2008-03-27 2014-05-23 Συνθεσεις και μεθοδοι για αναστολη toy pdgfrb και toy vegf-a

Country Status (14)

Country Link
US (2) US9441034B2 (el)
EP (3) EP2604280A3 (el)
JP (3) JP5425180B2 (el)
AU (3) AU2009228158B2 (el)
CA (1) CA2716882A1 (el)
CY (1) CY1115382T1 (el)
DK (1) DK2274008T3 (el)
ES (1) ES2456296T3 (el)
HR (1) HRP20140244T1 (el)
IL (3) IL207618A (el)
PL (1) PL2274008T3 (el)
PT (1) PT2274008E (el)
SI (1) SI2274008T1 (el)
WO (1) WO2009120922A2 (el)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3345616A1 (en) 2006-03-31 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
JP2012521768A (ja) * 2009-03-27 2012-09-20 ジモジェネティクス・インコーポレイテッド 抗体−受容体の組み合わせを含む多特異的結合性タンパク質を用いるための組成物および方法
WO2012010548A1 (en) 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
RU2013104039A (ru) 2010-07-19 2014-08-27 Ф. Хоффманн-Ля Рош Аг Способ идентификации пациента с повышенной вероятностью ответа на противораковую терапию
TWI638833B (zh) * 2010-11-30 2018-10-21 中外製藥股份有限公司 細胞傷害誘導治療劑
US9499608B2 (en) 2011-06-08 2016-11-22 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Bispecific monoclonal antibody therapeutics against West Nile virus with improved CNS penetration
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
KR102398736B1 (ko) 2011-10-31 2022-05-16 추가이 세이야쿠 가부시키가이샤 중쇄와 경쇄의 회합이 제어된 항원 결합 분자
JP6483442B2 (ja) * 2011-12-05 2019-03-13 エックス−ボディ インコーポレイテッド Ｐｄｇｆ受容体ベータ結合ポリペプチド
SG10201704846VA (en) * 2012-03-14 2017-07-28 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
EP2891497B1 (en) * 2012-08-31 2020-07-01 Osaka University Dna vaccine containing vegf-specific epitope and/or angiopoietin-2-specific epitope
EP2890836B1 (en) * 2012-08-31 2019-07-17 The Scripps Research Institute Methods related to modulators of eukaryotic cells
US9777067B2 (en) 2012-09-27 2017-10-03 Massachusetts Institute Of Technology HER2- and VEGF-A-binding proteins with enhanced stability
JO3405B1 (ar) * 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
LT2968461T (lt) * 2013-03-13 2022-12-27 Genzyme Corporation Sulieti baltymai, apimantys pdgf ir vegf surišančius fragmentus, ir jų panaudojimo būdai
CN104341504B (zh) 2013-08-06 2017-10-24 百奥泰生物科技(广州)有限公司 双特异性抗体
HUE058272T2 (hu) 2013-11-06 2022-07-28 Janssen Biotech Inc Anti-CCL17 antitestek
PL3094351T3 (pl) 2014-01-15 2022-06-27 Kadmon Corporation, Llc Środki immunomodulujące
WO2015113055A2 (en) 2014-01-27 2015-07-30 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Plant-derived antibodies and derivatives that reduce risk of antibody-dependent enhancement (ade) of infection
NZ724710A (en) 2014-04-07 2024-02-23 Chugai Pharmaceutical Co Ltd Immunoactivating antigen-binding molecule
CN106459954A (zh) 2014-05-13 2017-02-22 中外制药株式会社 用于具有免疫抑制功能的细胞的t细胞重定向的抗原结合分子
WO2015187835A2 (en) 2014-06-06 2015-12-10 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
WO2015197593A1 (en) * 2014-06-27 2015-12-30 Innate Pharma MULTISPECIFIC NKp46 BINDING PROTEINS
MX2016017290A (es) * 2014-06-28 2017-08-24 Kodiak Sciences Inc Antagonistas duales de factor de crecimiento derivado de plaquetas (pdgf)/factor de crecimiento endotelial vascular (vegf).
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
CN107208076A (zh) 2014-10-17 2017-09-26 科达制药 丁酰胆碱酯酶两性离子聚合物缀合物
AR102417A1 (es) * 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
CA2980385A1 (en) 2015-03-20 2016-09-29 Johann Wolfgang Goethe-Universitat Frankfurt Am Main Pericyte long non-coding rnas
CN107743586B (zh) 2015-06-03 2021-07-02 百时美施贵宝公司 用于癌症诊断的抗gitr抗体
MY189159A (en) 2015-07-06 2022-01-29 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
US10308711B2 (en) 2015-08-14 2019-06-04 Allergan, Inc. Heavy chain only antibodies to PDGF
TWI799366B (zh) * 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
AR106184A1 (es) 2015-09-29 2017-12-20 Celgene Corp Proteínas de unión a pd-1 y sus métodos de uso
CA3003243A1 (en) * 2015-10-30 2017-05-04 Eli Lilly And Company Anti-cgrp/anti-il-23 bispecific antibodies and uses thereof
WO2017086367A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
US11649293B2 (en) 2015-11-18 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
CA3005855A1 (en) 2015-11-19 2017-05-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
WO2017106609A2 (en) * 2015-12-16 2017-06-22 Kadmon Corporation, Llc. Pdgfr beta antibody
CN108366968B (zh) 2015-12-16 2022-02-18 瑞泽恩制药公司 制造蛋白质微粒的组合物和方法
BR112018009312A8 (pt) 2015-12-28 2019-02-26 Chugai Pharmaceutical Co Ltd método para promover eficiência de purificação de polipeptídeo contendo região de fc
CA3010056A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
RU2746754C2 (ru) 2016-03-14 2021-04-20 Чугаи Сейяку Кабусики Кайся Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии
WO2017190079A1 (en) 2016-04-28 2017-11-02 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
RU2656160C2 (ru) 2016-08-17 2018-05-31 Закрытое Акционерное Общество "Биокад" Антитело или его антигенсвязывающий фрагмент, способный связываться с рецептором интерлейкина-6 человека
EP3783022A3 (en) * 2016-08-23 2021-06-30 MedImmune Limited Anti-vegf-a antibodies and uses thereof
EP3515944A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHODS OF TREATING IMMUNE DISORDERS WITH PD-1 BINDING PROTEINS
EP3515943A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
MY201744A (en) * 2016-12-23 2024-03-15 Visterra Inc Binding polypeptides and methods of making the same
KR101908330B1 (ko) * 2017-02-17 2018-10-16 인제대학교 산학협력단 신규 항-vegf 항체 및 이를 유효성분으로 포함하는 나이관련 황반변성 예방 또는 치료용 조성물
SG11201907948TA (en) * 2017-03-29 2019-09-27 Celgene Corp Formulations comprising pd-1 binding proteins and methods of making thereof
JP6911490B2 (ja) * 2017-04-26 2021-07-28 東ソー株式会社 安定型Ｆｃ結合性タンパク質、当該タンパク質の製造方法および当該タンパク質を用いた抗体吸着剤
KR20200006115A (ko) 2017-05-16 2020-01-17 브리스톨-마이어스 스큅 컴퍼니 항-gitr 효능제 항체에 의한 암의 치료
CN109022415B (zh) * 2017-06-12 2023-09-15 上海睿智化学研究有限公司 PDGFRβ单克隆重链抗体杂交瘤细胞及其制备方法和应用
CN111279024A (zh) 2017-08-21 2020-06-12 天演药业公司 动态人重链抗体文库
BR112020003459A2 (pt) * 2017-08-21 2020-08-25 Adagene Inc. bibliotecas, animal não humano, fago, cadeia leve de anticorpo, anticorpos, métodos para preparar uma biblioteca, para produzir uma biblioteca de anticorpos e para gerar um anticorpo biespecífico e kit
CN108094772A (zh) * 2017-12-08 2018-06-01 桂林莱茵生物科技股份有限公司 一种罗汉果果汁及其制备方法
BR112020017872A2 (pt) * 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
CN112996805A (zh) 2018-08-30 2021-06-18 Hcw生物科技公司 多链嵌合多肽和其用途
JP7407822B2 (ja) 2018-08-30 2024-01-04 エイチシーダブリュー バイオロジックス インコーポレイテッド 単鎖キメラポリペプチドおよびその使用
CN112888445A (zh) 2018-08-30 2021-06-01 Hcw生物科技公司 治疗老年化相关病症的方法
EP3868781A4 (en) * 2018-10-05 2022-07-06 Seoul National University R & DB Foundation PDGF RECEPTOR ANTIBODIES AND ITS USE
WO2020088164A1 (zh) * 2018-11-01 2020-05-07 山东新时代药业有限公司 双特异性抗体及其用途
WO2020257639A1 (en) 2019-06-21 2020-12-24 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
CN112168971B (zh) * 2019-07-03 2023-04-04 义慧科技(深圳)有限公司 抗vegf抗体和pdgf/pdgfr抑制剂在制备治疗表达fgf2肿瘤的药物的应用
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
KR20220140551A (ko) * 2020-02-07 2022-10-18 바이오리온 테크놀러지스 비.브이. 혈소판 유래 성장 인자 수용체(pdgfr) 항체, 이의 컨쥬게이트, 조성물 및 용도
IL295084A (en) 2020-02-11 2022-09-01 Hcw Biologics Inc Chromatography resin and its uses
AU2021220870A1 (en) 2020-02-11 2022-08-04 HCW Biologics, Inc. Methods of treating age-related and inflammatory diseases
IL295083A (en) 2020-02-11 2022-09-01 Hcw Biologics Inc Methods for activating regulatory t cells
CN115836087A (zh) 2020-04-29 2023-03-21 Hcw生物科技公司 抗cd26蛋白及其用途
IL298608A (en) 2020-06-01 2023-01-01 Hcw Biologics Inc Methods for treating disorders related to aging
WO2021247003A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体系统
BR112023024724A2 (pt) * 2021-05-28 2024-02-15 Dana Farber Cancer Inst Inc Construtos de anticorpos multiespecíficos contra o muc1-c/domínio extracelular (muc1-c/ecd)
CA3233246A1 (en) * 2021-09-29 2023-04-06 Dragonfly Therapeutics, Inc. Antibodies targeting baff-r and use thereof
WO2023164510A1 (en) * 2022-02-23 2023-08-31 Xencor, Inc. Anti-cd28 x anti-psma antibodies
WO2023168363A1 (en) 2022-03-02 2023-09-07 HCW Biologics, Inc. Method of treating pancreatic cancer
WO2024044732A2 (en) * 2022-08-25 2024-02-29 Bright Biopharmaceutical Multispecific antibodies and uses thereof

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK368882A (da) 1981-08-25 1983-02-26 Alan John Kingsman Expessions vektorer
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4977092A (en) 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US5139936A (en) 1983-02-28 1992-08-18 Collaborative Research, Inc. Use of the GAL1 yeast promoter
US4661454A (en) 1983-02-28 1987-04-28 Collaborative Research, Inc. GAL1 yeast promoter linked to non galactokinase gene
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4990446A (en) 1984-12-06 1991-02-05 Labofina, S.A. Promoters for the expression of foreign genes in yeast, plasmids comprising them, and use thereof for the production of polypeptides
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5063154A (en) 1987-06-24 1991-11-05 Whitehead Institute For Biomedical Research Pheromone - inducible yeast promoter
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5268358A (en) 1988-12-08 1993-12-07 Cor Therapeutics, Inc. PDGF receptor blocking peptides
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
JP3202999B2 (ja) 1991-01-31 2001-08-27 協和醗酵工業株式会社 肝移行性リポソーム製剤
CA2100559C (en) 1991-01-31 2007-05-22 David Wolf Domains of extracellular region of human platelet derived growth factor receptor polypeptides
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
US5298418A (en) 1991-09-16 1994-03-29 Boyce Thompson Institute For Plant Research, Inc. Cell line isolated from larval midgut tissue of Trichoplusia ni
AU2861692A (en) 1991-10-18 1993-05-21 Beth Israel Hospital Association, The Vascular permeability factor targeted compounds
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US5817310A (en) 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
US20020009443A1 (en) * 1991-12-02 2002-01-24 Vanitha Ramakrishman Inhibitory immunoglobulin polypeptides to human pdgf beta receptor
AU5103293A (en) 1992-09-14 1994-04-12 Oklahoma State University Immortalized cells and uses therefor
DK1167384T3 (da) 1992-10-28 2007-04-10 Genentech Inc Vaskular endotheliel cellevækstfaktor antagonister
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US5641655A (en) 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
US5654173A (en) 1996-08-23 1997-08-05 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US5716808A (en) 1995-11-09 1998-02-10 Zymogenetics, Inc. Genetic engineering of pichia methanolica
US5955349A (en) 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US5854039A (en) 1996-07-17 1998-12-29 Zymogenetics, Inc. Transformation of pichia methanolica
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
US20070059302A1 (en) * 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
DE69829891T2 (de) * 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
KR20020092779A (ko) * 1999-06-03 2002-12-12 휴먼 게놈 사이언시즈, 인코포레이티드 혈관형성 단백질 및 이의 용도
US20020103345A1 (en) 2000-05-24 2002-08-01 Zhenping Zhu Bispecific immunoglobulin-like antigen binding proteins and method of production
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
WO2002085923A2 (en) 2001-04-19 2002-10-31 The Scripps Research Institute In vivo incorporation of unnatural amino acids
CN100423777C (zh) 2001-10-25 2008-10-08 杰南技术公司 糖蛋白组合物
EP1487879B1 (en) 2002-03-01 2012-12-26 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
CA2489469C (en) 2002-06-14 2016-03-22 Immunomedics, Inc. Monoclonal antibody pam4 and its use for diagnosis and therapy of pancreatic cancer
CA2488924A1 (en) 2002-06-18 2003-12-24 Zymogenetics, Inc. Hybrid vector having a cytomegalovirus enhancer and myeloproliferative sarcoma virus promoter
EP1558647B1 (en) 2002-11-08 2015-06-10 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
EP1651663B1 (en) 2003-08-08 2017-05-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
KR101501870B1 (ko) * 2003-08-27 2015-03-12 옵쏘테크 코포레이션 안구의 혈관신생성 장애를 치료하기 위한 조합 치료법
AU2004273615B2 (en) 2003-09-23 2009-01-15 Novartis Ag Combination of a VEGF receptor inhibitor with a chemotherapeutic agent
US20050282233A1 (en) * 2004-03-05 2005-12-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
WO2006020258A2 (en) 2004-07-17 2006-02-23 Imclone Systems Incorporated Novel tetravalent bispecific antibody
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
KR20080090441A (ko) 2005-12-21 2008-10-08 메디뮨 엘엘씨 Ｅｐｈａ２ ｂｉｔｅ 분자 및 이의 용도
WO2007140534A1 (en) * 2006-06-08 2007-12-13 Csl Limited Vegf-a cross-reactive anti- vegf-b antibodies as antagonists of vegf-a and vegf-b signalling
WO2007147019A2 (en) * 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
CN101663319A (zh) 2007-02-21 2010-03-03 埃博灵克斯股份有限公司 针对血管内皮生长因子的氨基酸序列和包括其的多肽用于治疗特征在于过量和/或病理性血管发生或新血管形成的病症和疾病
AU2008242444B2 (en) 2007-04-17 2013-05-02 Imclone Llc PDGFRBeta-specific inhibitors
EP2212432A4 (en) * 2007-10-22 2011-10-19 Schering Corp COMPLETELY HUMAN ANTI-VEGF ANTIBODIES AND USE PROCEDURES

Also Published As

Publication number Publication date
JP2011518546A (ja) 2011-06-30
IL207618A0 (en) 2010-12-30
PT2274008E (pt) 2014-05-12
ES2456296T3 (es) 2014-04-21
WO2009120922A2 (en) 2009-10-01
AU2009228158B2 (en) 2014-02-27
JP5425180B2 (ja) 2014-02-26
CA2716882A1 (en) 2009-10-01
AU2014202867A1 (en) 2014-06-19
SI2274008T1 (sl) 2014-08-29
JP6140796B2 (ja) 2017-05-31
EP2604279A1 (en) 2013-06-19
US20110177074A1 (en) 2011-07-21
AU2014202867B2 (en) 2016-11-10
AU2009228158A1 (en) 2009-10-01
AU2016273894A1 (en) 2017-01-05
PL2274008T3 (pl) 2014-07-31
EP2274008A2 (en) 2011-01-19
IL235619A (en) 2017-03-30
JP2016127824A (ja) 2016-07-14
JP2014073129A (ja) 2014-04-24
EP2604280A2 (en) 2013-06-19
JP5855627B2 (ja) 2016-02-09
IL235618A (en) 2016-12-29
US20160311909A1 (en) 2016-10-27
DK2274008T3 (da) 2014-05-12
HRP20140244T1 (hr) 2014-04-11
EP2604280A3 (en) 2013-10-16
WO2009120922A3 (en) 2009-12-17
IL207618A (en) 2014-11-30
US9441034B2 (en) 2016-09-13
US9708390B2 (en) 2017-07-18
EP2274008B1 (en) 2014-02-26

Similar Documents

Publication Publication Date Title
CY1115382T1 (el) Συνθεσεις και μεθοδοι για αναστολη toy pdgfrb και toy vegf-a
CY1121025T1 (el) ΑΝΤΙΣΩΜΑ ANTI-cMET
CY1122669T1 (el) Σκευασματα αντισωματων αντισκληροστινης υψηλης συγκεντρωσης
CY1123739T1 (el) Αντισωματα anti-cd38
PH12019500193A1 (en) Chimeric antigen receptors targeting bcma and methods of use thereof
CY1120359T1 (el) Σταθερες φαρμακοτεχνικες μορφες αντισωματων εναντι ανθρωπινου υποδοχεα pd-1 προγραμματισμενου θανατου και σχετικες θεραπειες
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
NZ743881A (en) Fabs-in-tandem immunoglobulin and uses thereof
BR112016025009A2 (pt) anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície
MX2019014318A (es) Proteinas de union a nectina-4 y metodos de uso de las mismas.
EA201792451A1 (ru) Антитела к ox40 и способы их применения
EA201070148A1 (ru) Соединения и способы модулирования фарнезоидного рецептора x (fxr)
EA201101009A1 (ru) АНТАГОНИСТЫ C5aR
EA201100133A1 (ru) Антагонисты рецепторов простагландина d
UA116873C2 (uk) Антитіло, яке зв'язується з ox40
EA201790330A1 (ru) Белки, связывающиеся с bcma (cd269/tnfrsf17)
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
BR112013021863A2 (pt) anticorpos anti-receptor il-6 e métodos de uso
EA201291180A1 (ru) Композиции и способы применения терапевтических антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
EA201391351A1 (ru) Способы повышения эффективности folr1 терапии рака
BR112013017947A2 (pt) benzoazepinas substituídas como moduladores de receptor toll-like
CO6351801A2 (es) Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos
EA200970810A1 (ru) Модифицированные полипептиды рецептора активина и их применение
EA201690633A1 (ru) Способы и композиции, включающие комбинацию антагониста vegf и анти-ctla-4 антитела
UA118332C2 (uk) Білок, що зв'язує антиген cd27l